SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares are surging significantly following a breakthrough in Phase 3 clinical trial results for its personalized cancer vaccine, which demonstrated improved recurrence-free survival in melanoma patients when used in combination with Merck's immunotherapy. The community reaction is highly polarized, with longs celebrating the massive gains and medical innovation, while vocal critics are expressing skepticism regarding the potential long-term safety of mRNA technology and the company's historical association with the COVID-19 vaccine.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is surging following the announcement of a massive multi-year partnership with Google, which includes a custom-chip deal and a significant equity warrant issuance. While bulls are celebrating the long-term revenue visibility and the company's strengthening position in the AI infrastructure space, the community is actively debating the potential for long-term share dilution and the volatility of the stock as traders react to the news.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is generating buzz as traders closely watch a crucial technical breakout point, with sentiment buoyed by expectations surrounding a high-profile industry gathering and ongoing debate over its role as a hedge against macroeconomic instability. The community remains deeply divided between those accumulating at these levels in anticipation of a cycle-driven bull market and skeptics bracing for potential volatility stemming from broader economic pressures.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is experiencing significant volatility driven by market concerns over potential off-balance-sheet debt risks and a high-profile security vulnerability in its VMware products. While the community is debating whether this pullback is a temporary overreaction or a structural shift, many investors are viewing the drop as an accumulation opportunity ahead of upcoming earnings.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending following a recent growth conference presentation that provided positive updates on the company's BLA filing progress and potential market opportunity for its aglatimagene prostate cancer therapy. Investors are actively discussing the firm's robust cash position, institutional accumulation, and the potential for a high-value acquisition, with many comparing the stock's clinical platform potential to other significant oncology success stories.

Target Corp. engages in the operation and ownership of general merchandise stores. It offers food and general merchandise, clothing and household goods, electronics, and toys. Its brands include A New Day, All in Motion, Art Class, Auden, AVA & VIV, Boots and Barkley, Brightroom, Bullseye's Playground, Casaluna, Cat & Jack, Cloud Island, Colsie, dealworthy, Embark, Everspring, Favorite Day, Figmint, Future Collective, Gigglescape, Good & Gather, Goodfellow & Co, Hearth & Hand with Magnolia, Heyday, Hyde & EEK! Boutique, JoyLab, Kindfull, Kona Sol, Made By Design, Market Pantry, Mondo Llama, More Than Magic, Opalhouse, Open Story, Original Use, Pillowfort, Project 62, Room Essentials, Shade & Shore, Smartly, Smith & Hawken, Sonia Kashuk, Spritz, Sun Squad, Threshold, Universal Thread, up&up, Wild Fable, Wondershop, Xhilaration, California Roots, Casa Cantina, The Collection, Headliner, Jingle & Mingle, Rosé Bae, Photograph, SunPop, and Wine Cube. The company was founded by George Draper Dayton in 1902 and is headquartered in Minneapolis, MN.

Target Corp

Target is trending as investors react to a significant earnings beat and raised full-year guidance, which has sparked intense debate over the stock's long-term turnaround potential despite a sharp initial price dip. Community sentiment remains polarized, with bulls pointing to the company's resilient digital growth and executive execution, while bears remain skeptical due to lingering consumer spending pressures and the stock's rapid year-to-date rally.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is facing significant volatility as investors weigh reports of Texas grid regulatory audits against the company's long-term infrastructure expansion. The community remains deeply divided between those adding to positions on dips due to bullish institutional ownership and hyperscaler partnerships, and those frustrated by erratic price action and the impact of sector-wide regulatory uncertainty.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is experiencing significant market interest driven by an acquisition of Personalis, which is being viewed as a strategic play to scale its precision oncology and minimal residual disease diagnostic platform. While short interest remains high, fueling speculation about potential squeeze dynamics, community sentiment is divided between those focused on the long-term potential of its healthcare AI data moat and those wary of near-term dilution and the deal's integration risks.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

The iShares 20+ Year Treasury Bond ETF (TLT) is trending as the Treasury Department doubles its buyback operation size to $4 billion to provide liquidity and stabilize long-term debt markets. Investors are actively debating whether this move acts as a necessary support for bond yields or a form of 'backdoor QE' that complicates the inflation outlook as they closely monitor upcoming Fed minutes and ongoing geopolitical pressures.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending as investors digest news of a personalized cancer vaccine trial breakthrough, while the company also faces intense buyout speculation regarding potential acquisitions to reinforce its oncology pipeline ahead of the Keytruda patent cliff. The market is actively debating Mercks long-term strategy, with community sentiment split between enthusiasm for its core product portfolio and concerns over how the firm will navigate impending competition.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UBS reiterated $IDYA at Buy-$50-Top Pick and said, we believe $IDYA&#39;s lead asset, darovasertib (daro), is a transformative therapy for uveal melanoma, yet underappreciated by the market - we est a $1.3B peak sales potential while the Street is pricing in $800M peak at the current stock price. 
 
We believe daro&#39;s impressive clinical efficacy, clean 
safety, and convenient oral dosing could enable its use over the current standard of care in front-line and neoadjuvant uveal melanoma. 
 
More importantly, we see several high conviction near-term catalysts over the next 6 months that could drive significant upside for the stock. 
These include 
1) daro Phase 2 readout in neoadjuvant enucleation cohort at ESMO medical conference (Oct 17-21), 
2) daro Phase 2 overall survival data in 1L metastatic uveal melanoma at SMR medical conference (Oct 25-28), and 
3) daro pivotal Phase 3 data in 1L metastatic uveal melanoma (HLA-A2-) in 4Q25-1Q26. 
 $GILD $SMMT $BNTX $DSNKY

Joe!

Mizuho reiterated $IDYA Outperform-$44 &amp; said we attended $IDYA&#39;s R&amp;D Day earlier this week, with the company featuring presentations on its five highest-priority R&amp;D assets: 
(1) darovasertib for uveal melanoma/UM; 
(2) IDE397, a novel MAT2A candidate for MTAP-deleted solid tumors; 
(3) IDE849, an emerging DLL3-TOP1 ADC candidate; 
(4) IDE161, a novel PARG inhibitor; and 
(5) IDE892, a potentially best-in-class PRMT5 inhibitor. 
 
Overall, we walked away positively, as we continue to be impressed by $IDYA&#39;s ability to execute. 
On lead asset daro, following the updates we heard (including supportive comments by an uveal melanoma expert), we increase our probability of 
success/POS assumption to 70% (vs. 60% prior) in the neoadjuvant UM setting, and on other model updates, our PT moves to $44. 
 
With the stock down 8% post-the R&amp;D Day event, additional pipeline newsflow expected in the near-term, and model upside from pipeline assets not currently modeled, we stay OP-rated on $IDYA. 
 
$AZN $RHHBY $BMY $ZLAB

StockTwits Web

Ideaya Biosciences Inc

AstraZeneca PLC

Roche Holdings AG ADR

Bristol-Myers Squibb Co.

Zai Lab Ltd

Quantumup

Citizens reiterated $IDYA Market Outperform-$45 and said, &#39;We Remain Bullish On IDYA&#39;s Upcoming ESMO Update That Can Help Investors To Estimate The PoS Of The Neoadjuvant Uveal Melanoma Opportunity.&#39; 
$IMCR $AURA 
Citizens additionally said:

Gilead Sciences, Inc.

Summit Therapeutics Inc

BioNTech SE - ADR

Daiichi Sankyo Company

 at Buy-$50-Top Pick and said, we believe 

's lead asset, darovasertib (daro), is a transformative therapy for uveal melanoma, yet underappreciated by the market - we est a $1.3B peak sales potential while the Street is pricing in $800M peak at the current stock price. 
 
We believe daro's impressive clinical efficacy, clean 
safety, and convenient oral dosing could enable its use over the current standard of care in front-line and neoadjuvant uveal melanoma. 
 
More importantly, we see several high conviction near-term catalysts over the next 6 months that could drive significant upside for the stock. 
These include 
1) daro Phase 2 readout in neoadjuvant enucleation cohort at ESMO medical conference (Oct 17-21), 
2) daro Phase 2 overall survival data in 1L metastatic uveal melanoma at SMR medical conference (Oct 25-28), and 
3) daro pivotal Phase 3 data in 1L metastatic uveal melanoma (HLA-A2-) in 4Q25-1Q26. 
 